AbbVie Inc. (NYSE:ABBV) Receives Average Rating of “Moderate Buy” from Brokerages

AbbVie Inc. (NYSE:ABBV) has been given an average recommendation of “Moderate Buy” by the twenty-five ratings firms that are currently covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $253.15.

ABBV has been the topic of a number of research analyst reports. William Blair reissued an “outperform” rating on shares of AbbVie in a report on Monday. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Piper Sandler raised their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. UBS Group reduced their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research report on Monday.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AbbVie

Several large investors have recently modified their holdings of the stock. Winthrop Partners WNY LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $1,317,000. Nalls Sherbakoff Group LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at approximately $76,000. Meadowbrook Advisors Group LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at approximately $2,056,000. Green Ridge Wealth Planning LLC bought a new position in AbbVie in the fourth quarter worth approximately $434,000. Finally, Advisortrust Partners LLC purchased a new position in shares of AbbVie during the fourth quarter valued at $659,000. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie advanced a risankizumab dosing Phase 1 study, signaling continued investment in immunology R&D that supports long‑term growth expectations. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: AbbVie’s ABBV‑295 reported encouraging Phase 1 results, adding to near‑term pipeline optionality that could drive upside if later‑stage data hold. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $260 target, reflecting bullish analyst conviction around Skyrizi/Rinvoq rollout and immunology growth potential. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Neutral Sentiment: Analyst fair‑value models moved only slightly and views are split — some see upside from immunology, others flag competition risk, leaving headline price targets largely unchanged. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
• Neutral Sentiment: Market research highlights expanding opportunities in indications like bipolar depression over the coming decade, a long‑term tailwind but not an immediate catalyst. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Competitive setback: UCB’s Bimzelx outperformed AbbVie’s Skyrizi in psoriatic arthritis data, raising market‑share and pricing risk for a key immunology franchise. AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
• Negative Sentiment: Reported insider selling drew negative attention and was cited as a near‑term headwind to sentiment and share price. AbbVie (NYSE:ABBV) Stock Price Down 1% on Insider Selling

AbbVie Price Performance

Shares of NYSE ABBV opened at $225.36 on Friday. The stock has a market cap of $398.47 billion, a PE ratio of 95.49, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34. AbbVie has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a fifty day moving average price of $224.52 and a 200-day moving average price of $224.48.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the company earned $2.16 EPS. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts expect that AbbVie will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.